Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus
- PMID: 1972484
- DOI: 10.1016/0140-6736(90)91373-i
Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus
Abstract
A prospective echocardiographic study was carried out on 132 consecutive patients with systemic lupus erythematosus (SLE) derived from three European university medical centres. The prevalence of valvular lesions in patients with SLE was 22.7% compared with 2.9% in a control group of 68 healthy volunteers. 50 SLE patients had antibodies against phospholipids. The prevalence of valve vegetations (8/50 [16%]) and of mitral regurgitation (19/50 [38%]) was significantly higher among the SLE patients with antiphospholipids than among those without (1 and 10/82 [1.2% and 12%], respectively). During follow-up of the patients with valvular lesions, haemodynamically significant clinical valve disease developed in 6 but surgery was required in only 1; 9 had cerebrovascular occlusions; and 7 died, although no death was due directly to the cardiac involvement. Thus, valvular heart disease, particularly affecting the mitral valve, is common in patients with SLE, and the presence of antibodies against phospholipids is associated with a higher prevalence of valvular abnormalities in these patients.
Comment in
-
Lack of association between anticardiolipin antibodies and heart valve disease in Chinese patients with systemic lupus erythematosus.Lancet. 1990 Aug 25;336(8713):504-5. doi: 10.1016/0140-6736(90)92052-j. Lancet. 1990. PMID: 1975008 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical